GL1X · GenesisL1 explorer

MolNFT v1 · #135140 · protein

Design and synthesis of a pan-JAK kinase inhibitor clinical candidate (pf-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin

5TQ3 · Tyrosine-protein kinase JAK2: “Design and synthesis of a pan-JAK kinase inhibitor clinical candidate (pf-06263276) suitable for the…”. X-ray diffraction, 1 ligand (7GZ), 4 pockets (best druggability 0.75). MolNFT v1 #135140 on…

PDB
5TQ3
Type
protein
Length
571 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein kinase JAK2
EC
2.7.10.2
UniProt
O60674
Ligands
7GZ
Pockets
4 · best druggability 0.75

Structure

x-ray diffraction · 2 distinct chains · 45% helix, 19% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein kinase JAK2 (EC 2.7.10.2)protein28445% helix, 19% strandO60674
BTyrosine-protein kinase JAK2 (EC 2.7.10.2)protein28745% helix, 19% strandO60674

Ligands and binding sites

  • 7GZ · 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-6-yl]-3-ethylphenol · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16130.750.82517GZ
26220.740.80557GZ
3760.630.9122empty
41610.510.7926empty

Interfaces

1 interface between chains.

  • A–B · 700 Ų buried · 8 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 modified (phosphorylation).

Compared structures

  • 5TQ3 · Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276)… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.